56 results about "Endothelial progenitor cell" patented technology

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

Platelet lysate compositions and cell culture media compositions for maintaining and / or growing mammalian cells, such as mammalian endothelial cells (ECs) and mammalian endothelial progenitor cells (EPCs), in particular human ECs (huECs) and human EPCs (huEPCs), such as primary huECs and primary huEPCs, are provided. The cell culture media compositions contain a basal medium, a platelet lysate and, optionally, one or more exogenously added growth factors. Also provided are methods for making and using such cell culture media compositions to grow and / or maintain ECs and EPCs, including huECs and huEPCs, as well as cell culture vessels, dishes, plates, and / or flasks pretreated with the cell culture media compositions.

The invention discloses an exosome loaded with baicalin, the exosome is derived from endothelial progenitor cells, and 0.5-1 mg / mL of a baicalin solution is encapsulated in each 1 mg / mL of an exosome solution. The invention also discloses a preparation method and application of the baicalin-loaded exosome. The application disclosed by the invention mainly has the beneficial effects that the effectiveness of BA in treating acute lung injury (especially sepsis acute lung injury) is confirmed for the first time; the key effect of BA in treating acute lung injury (especially sepsis acute lung injury) by activating ALDH2 is determined for the first time; the action mechanism of BA for treating acute lung injury (especially sepsis acute lung injury) by regulating cell ferroptosis is clarified for the first time; the exosome derived from endothelial progenitor cells is adopted to load BA so as to treat acute lung injury caused by sepsis; the invention provides a brand new mechanism and treatment means for the treatment strategy of acute lung injury (especially sepsis acute lung injury).

Provided is the use of RAP2C in the breeding of Blcattle black cattle, belonging to the technical field of molecular biological breeding. RAP2C can be used for the breeding of Blcattle black cattle, and individuals having a high RAP2C content are screened as high-quality calves and alternative breeding cattle. In the present disclosure, it is proved by means of experiments that RAP2C can promote the differentiation of vascular endothelial progenitor cells to regulate placental angiogenesis, enhance placental blood flow and increase placental nutrient transport efficiency in Blcattle black cattle, thereby regulating calf birth weight. The present disclosure provides a new direction for the breeding of high-quality beef cattle of Blcattle black cattle.

The invention discloses a new application of Apo-EVs, and particularly discloses an application of Apo-EVs from endothelial cells (ECs) in promoting differentiation of endothelial progenitor cells (EPCs) and wound healing. The Apo-EVs is rich in miR-30a-5p, and can significantly promote the differentiation of EPCs to ECs and accelerate the angiogenesis through targeted regulation of EGFR / PI3K / AKT / VEGF signal channels. In a mouse wound healing model, the Apo-EVs is adopted for intervention, and the wound healing time can be effectively shortened. The invention provides a natural, efficient and low-toxicity wound repair biological agent, and provides a new strategy for treatment of ischemic diseases and refractory wounds.

The invention belongs to the field of cell preparations, and relates to a culture medium suitable for a cell population containing mesenchymal stem cells, the culture medium comprises a component 1 MEM-alpha, and 5% of a serum substitute is added; component 2: MEM-alpha added with a human bFGF, a human EGF and a human VEGF, wherein the final concentration of the human bFGF, the final concentration of the human EGF and the final concentration of the human VEGF are all 10 ng / ml; wherein the addition amount of the component 2 in the component 1 is less than or equal to 10%; wherein the component 1 is a culture medium adopted during subculture of MSC (mesenchymal stem cells); and the component 2 is an endothelial progenitor cell culture medium. In the culture process of the MSC cells, introduction of animal-derived components is avoided; meanwhile, the content of endothelial progenitor cells carried by the umbilical cord in the process of obtaining the MSC is regulated and controlled, and the optimal performance of the MSC is kept.

The invention discloses a human endothelial progenitor cell culture medium and application thereof in preparation of extracellular vesicles. The formula of the human endothelial progenitor cell culture medium is as follows: human platelet lysate with the volume concentration of 3-10%, VEGF (vascular endothelial growth factor) with the volume concentration of 60-200ng / mL, IGF (insulin-like growth factor) with the volume concentration of 20-100ng / mL, L-glutamine with the volume concentration of 2-10mM, sodium pyruvate with the volume concentration of 0.02-0.75 mM, glucocorticoid with the volume concentration of 50-250ng / mL and a reducing agent with the volume concentration of 50-200mu M are added into a basic cell culture medium; the human endothelial progenitor cells are human placenta tissue-derived endothelial progenitor cells. Animal-derived reagents are not involved, the price is low, the number of EPCs extracellular vesicles obtained through amplification is large, the purity is high, and the skin wound repairing effect is good. The extracellular vesicles are easy to produce on a large scale, convenient to store and control batch quality, simple to obtain and use and free of immunological rejection.

This invention relates to an intravascular blood flow guiding device with an endothelialization-promoting coating. After the coating is applied to the surface of the blood flow guiding device, it can regulate the biological functions of circulating endothelial progenitor cells within the blood vessel, including promoting oriented extracellular matrix formation, promoting cell-extracellular matrix adhesion, and promoting endothelial cell proliferation and maturation. This results in: enhanced adhesion, proliferation, and migration capabilities of endothelial progenitor cells; significantly improved acceleration of the endothelialization process; excellent anti-platelet and anti-SMC adhesion properties; and, combined with the hemodynamic optimization effect of the blood flow guiding device, accelerated functional remodeling of the tumor-bearing artery.

The invention relates to the technical field of biological medicine, in particular to a culture medium for vascular endothelial progenitor cells, a culture method and application, the culture medium for the vascular endothelial progenitor cells is improved, and the prepared vascular endothelial progenitor cells have higher proliferative activity and better angiogenesis ability and have the strongest ability of promoting secretion of active factors. Factors such as IL-10 and TGF-beta secreted by the EPCs have potential functions of inhibiting mast cell degranulation and reducing release of histamine and inflammatory mediators so as to relieve wind mass and pruritus. In addition, the EPCs promote endothelial cell proliferation by secreting VEGF, Ang-1 and other factors, repair damaged vascular endothelium and reduce vascular leakage and edema. In urticaria vasculitis, the EPCs can inhibit hyperplasia of vascular endothelium and relieve chronic inflammation. The culture medium disclosed by the invention can be used for culturing the vascular endothelial progenitor cells, is beneficial to screening potential medicines for treating urticaria, and has a huge application value.

The invention discloses a human placenta-derived endothelial progenitor cell and a combined drug thereof as well as application of the human placenta-derived endothelial progenitor cell in preparation of a drug for treating radiation-induced thymus injury, and discloses a novel cell treatment drug for reconstructing a thymus microenvironment, recovering T cell generation and promoting thymus function repair and immune reconstruction aiming at thymus radiation injury. The placenta-derived endothelial progenitor cells are found to have an excellent effect of treating the radiation thymus injury, and the human placenta-derived endothelial progenitor cells and the human umbilical cord mesenchymal stem cells are synergistically combined to have a synergistic effect on treating the radiation thymus injury.

The invention provides a stem cell composition for treating male erectile dysfunction and a preparation method thereof, and belongs to the technical field of medicines. Adding the magnetic particles loaded with the platelet-derived growth factors and the matrix metalloproteinase into a culture medium, activating the amniotic mesenchymal stem cells, and separating to obtain the activated amniotic mesenchymal stem cells, paracrine compositions and magnetic nutrient particles, and mixing the stem cells with an intercalation sustained-release drug compound and a penetration enhancing and activating agent, and adding the mixture into a temperature-sensitive hydrogel sustained-release system to prepare the stem cell composition for treating male erectile dysfunction. The stem cell composition for treating male erectile dysfunction plays a role through multiple ways, promotes angiogenesis, improves penis hemodynamics, inhibits smooth muscle cell apoptosis, adjusts neurological functions, enhances endothelial progenitor cell recruitment and the like, so that damaged penis tissues are more comprehensively repaired and regenerated, and the male erectile dysfunction treatment effect is improved. Wide application prospects are realized.

The present technology comprises isolated endothelial progenitor cell (EPC) populations and mesenchymal stem cell (MSC) populations, and methods of making and using the same for treating bleeding disorders, including Von Willebrand Disease, and associated symptoms.

A health care apparatus (2, 2'), used for transmitting a low-frequency wave (W) to the spine or umbilicus so as to increase the number of endothelial progenitor cells (EPCs) and reduce the number of circulating endothelial cells (CECs), thus reducing the risk of cardiovascular-related adverse events. The health care apparatus (2, 2') comprises a box body (21, 21') and a power supply (22, 22'), a speed controller (23, 23'), a rotary mechanism (24, 24'), a connecting rod mechanism (25, 25'), a knocker (26, 26'), and a conical platform (27, 27') which are provided in the box body (21, 21'). The power supply (22, 22') is electrically connected to the speed controller (23, 23') so as to output power to the speed controller (23, 23'). The speed controller (23, 23') is electrically connected to the rotary mechanism (24, 24') and controls rotation of the rotary mechanism (24, 24') at a predetermined speed. The rotary mechanism (24, 24') is connected to the knocker (26, 26') by means of the connecting rod mechanism (25, 25') so as to drive the knocker (26, 26') to knock on a flat surface of the conical platform (27, 27'), and the knocker (26, 26') generates a low-frequency wave (W) of a predetermined frequency. Further provided is the use of the health care apparatus (2, 2') in transmitting a low-frequency wave (W) to the spine or umbilicus.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

This invention discloses a cell therapy drug for treating diseases related to steatosis. The cell therapy drug comprises endothelial progenitor cells or endothelial cells derived from iPSC differentiation. This invention demonstrates that intravenous injection of iPSC-derived endothelial progenitor cells into an animal model of fatty liver disease can treat fatty liver disease by reducing steatosis in liver tissue. The research findings of this invention provide a novel treatment approach for clinical treatment of diseases related to steatosis, especially fatty liver disease.

The present invention provides a method for constructing a sinusoidal network liver organoid and its application, wherein pluripotent stem cells are co-differentiated into HAND1 + Mesoderm and endoderm produce KDR + Mesodermal progenitors give rise to the posterior foregut endoderm, which has CD34 + / CD31 + Endothelial progenitor cells form hepatic endoderm and form a sinusoidal network in liver organoids. These liver organoids possess a functional sinusoidal endothelial network throughout the liver clusters, exhibiting characteristic functions such as low-density lipoprotein uptake, human serum albumin clearance, and secretion of coagulation factor 8. This method provides a new generation of highly biomimetic research tools for understanding liver disease mechanisms, drug screening, and regenerative repair.

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None

The invention discloses a method for differentiating NK (Natural Killer) cells. Hematopoietic endothelial cells (HEC), hematopoietic endothelial progenitor cells (HEPC) or hematopoietic stem progenitor cells (HSPC) are differentiated into the NK cells under the condition of co-culture with human mesenchymal-like cells. The method has the advantages that the use of heterogeneous stromal cells is avoided in the early stage of NK cell differentiation, the yield of the NK cells is greatly improved, the average number of NK cells generated by a single pluripotent stem cell can reach about 1500, the number is improved by 15-150 times compared with an existing differentiation system, and the method is suitable for large-scale production. Therefore, engineering K562 tumor cells do not need to be used for further amplifying the NK cells to meet the use quantity in the later period. And heterogeneous stromal cells are not used, so that the whole operation is simple and convenient, the repeatability is high, and the risk of animal-derived pollution is avoided. In addition, compared with the traditional NK cell differentiation which needs 2-3 months, the method shortens the differentiation time to about 1 month.

The application relates to the technical field of blood vessel health assessment, in particular to a blood vessel age assessment system and method based on rare cell dynamic monitoring, which comprises the following steps: acquiring current absolute counts of circulating endothelial cells, endothelial progenitor cells and inflammatory monocytes in peripheral blood; acquiring an apoptosis index of the circulating endothelial cells; generating a corrected current value; performing scale correction on each trend slope and the apoptosis index; performing weighted summation on the current value of the circulating endothelial cells, the trend slope of the current value of the circulating endothelial cells after scale correction, the normalized absolute count ratio value, the trend slope of the normalized absolute count ratio value after scale correction, the corrected current value and the trend slope of the corrected current value after scale correction by using preset weights respectively to generate a long-acting value; generating a transient value, accumulating the long-acting value and the transient value to synthesize a decay index; performing mapping conversion on the decay index to output a blood vessel age assessment result. The application can solve the problem of inflammation misjudgment of aging and realize accurate assessment of blood vessel age.

The invention relates to the technical field of organoid culture, in particular to a construction method of a heart-liver symbiotic organoid, which comprises the following steps: performing directional differentiation on human induced pluripotent stem cells by using Activin A, BMP4, a B27 culture additive (insulin removal type) and double antibodies to obtain endoderm / mesoderm; in the process of inducing endoderm / mesoderm to the progenitor cells, VEGF-A, bFGF, FGF4, BMP2 and double antibodies are added into a culture medium at the same time, and HUVECs are added when differentiation is carried out to the eighth day, so that a culture in which the hepatic progenitor cells and endothelial progenitor cells are symbiotic is obtained. The construction method provided by the invention not only can realize simultaneous differentiation of symbiotic myocardial organs and liver organs in the same differentiation system, but also comprises other non-parenchymal cell types. The invention further provides a supplement composition which can be used for maintaining the functions of the heart-liver symbiotic organs and prolonging the survival time of the heart-liver symbiotic organs. By adding the supplement composition, the contraction time and the liver functions of the heart-liver symbiotic organs can be remarkably increased.

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

The present invention relates to an umbilical cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases comprising the same, and more specifically, to an umbilical cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases, the present invention relates to a high-purity umbilical cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen characteristics, a method for obtaining an umbilical cord blood-derived vascular endothelial progenitor cell by pre-treating umbilical cord blood, and a composition for preventing and treating ischemic diseases comprising the umbilical cord blood-derived vascular endothelial progenitor cell. The high-purity umbilical cord blood-derived vascular endothelial progenitor cell of the present invention exhibits colony formation, high proliferation ability, and high potential for angiogenesis in vivo, and thus can exhibit an excellent effect on the prevention or treatment of various ischemic diseases induced by blood vessel contraction or occlusion.

A method for manufacturing a vascular structure comprising: a) the fabrication of elements comprising at least one core comprising at least one biopolymer, and endothelial cells and / or endothelial progenitor stem cells on its outer periphery; b) the placement of said elements in a fluidic chamber so that they form at least one stack; c) the establishment of a fluid flow ensuring nutrient and oxygenation supply through the stack so as to create channels between the elements along the flow lines. No abstract figure.

The present application relates to a method for producing a three-dimensional (3D) model of multiple myeloma (MM) in spheroid form by co-culturing mesenchymal stem / stromal cells, endothelial progenitor cells and primary plasma cells of an MM patient. The present application also relates to spheroids obtained by said method and uses thereof.

The invention relates to the technical field of biomedicine, in particular to an automatic analysis and risk assessment system and method for peripheral blood endothelial progenitor cells, and the method comprises the following steps: collecting a peripheral blood sample and clinical data of a subject; the method comprises the following steps: enriching CD34 + cells from a peripheral blood sample based on microfluidic-immunomagnetic bead enrichment, carrying out VEGFR2 and DAPI immunofluorescent staining on the enriched cells, and obtaining a multi-channel fluorescent digital image; analyzing the multi-channel fluorescent digital image, identifying and counting VEGFR < 2 + > and DAPI < + > double-positive cells to obtain an EPC counting result; inputting the EPC counting result and clinical data of the subject into a multi-modal AI risk assessment model to obtain a risk assessment result; the health management suggestion information is formulated based on the risk assessment result, so that the model can have better suitability with the target subject, and the accuracy of risk assessment is improved.

A health care device and an use thereof are configured to transmit a low frequency wave to a spine or navel to increase the number of endothelial progenitor cells (EPC) and to reduce the number of the circulating endothelial cells (CEC), which may reduce the risk of cardiovascular-related adverse diseases. The health care device includes a box body, a power supply, a speed controller, a rotating mechanism, a linkage mechanism, a knocker and a conical table. The power supply is electrically connected to the speed controller to output electricity to the speed controller. The speed controller is electrically connected to the rotating mechanism and controls the rotating mechanism to rotate at a predetermined speed. The rotating mechanism is connected to the knocker to drive the knocker to knock a flat surface of the conical table. The knocker generates the low frequency wave with a predetermined frequency.

The present invention relates to the prevention, improvement, or treatment of vascular diseases caused by aging of vascular endothelial progenitor cells containing Stemregenin-1. More specifically, Stemregenin-1 has excellent effects in protecting vascular endothelial progenitor cells from stress and aging experienced during various in vitro cultures while maintaining the cell-specific characteristics, proliferative ability, motility, and differentiation ability of vascular endothelial progenitor cells, and thus can be applied to the prevention, improvement, or treatment of vascular diseases caused by aging of vascular endothelial progenitor cells.

The application belongs to the field of medical devices and surface functional modification of biological materials, and particularly relates to a natural biological driving long-stable anti-thrombus and endothelialization improved blood flow guiding device and a preparation method. The specific biological functional molecule layer provided by the application can realize natural anti-blood coagulation in the initial implantation stage, natural biological driving endothelialization progress, and long-stable anti-thrombus formation. The specific biological functional molecule layer combines endothelial progenitor cells and endothelial cells to realize specific endothelial progenitor cell capture, differentiation, endothelial cell adhesion, migration and proliferation, so as to maximize effective re-endothelialization and ensure natural biological characteristics, realize natural remodeling of the inner wall of a blood vessel to achieve long-stable anti-thrombus, and is a new functional concept that is difficult to achieve by other solutions in the prior art. The application is a surface improved blood guiding device with natural anti-coagulation and natural biological driving endothelialization progress to obtain long-stable anti-thrombus.

The present disclosure relates to a cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases containing the same, and more specifically, to a highly pure cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen properties, a method for obtaining a cord blood-derived vascular endothelial progenitor cell through preprocessing of cord blood, and a composition for preventing or treating ischemic disease containing the cord blood-derived vascular endothelial progenitor cell. The high-purity cord blood-derived vascular endothelial progenitor cell of the present disclosure exhibits colony formation and high proliferation ability and angiogenic potential in the body, and thus can exhibit excellent effects in the prevention or treatment of various ischemic diseases caused by vascular contraction or occlusion.